| Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity L Vanderbeke, P Van Mol, Y Van Herck, F De Smet, S Humblet-Baron, ... Nature communications 12 (1), 4117, 2021 | 204 | 2021 |
| Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases E Dreesen, B Verstockt, S Bian, M de Bruyn, G Compernolle, S Tops, ... Clinical Gastroenterology and Hepatology 16 (12), 1937-1946. e8, 2018 | 147 | 2018 |
| Ustekinumab exposure-outcome analysis in Crohn’s disease only in part explains limited endoscopic remission rates B Verstockt, E Dreesen, M Noman, A Outtier, N Van den Berghe, I Aerden, ... Journal of Crohn's and Colitis 13 (7), 864-872, 2019 | 101 | 2019 |
| Software tools for model-informed precision dosing: how well do they satisfy the needs? W Kantasiripitak, R Van Daele, M Gijsen, M Ferrante, I Spriet, E Dreesen Frontiers in pharmacology 11, 620, 2020 | 86 | 2020 |
| Variability in golimumab exposure: a ‘real-life’observational study in active ulcerative colitis I Detrez, E Dreesen, T Van Stappen, A de Vries, E Brouwers, ... Journal of Crohn's and Colitis 10 (5), 575-581, 2016 | 85 | 2016 |
| Monitoring a combination of calprotectin and infliximab identifies patients with mucosal healing of Crohn’s disease E Dreesen, F Baert, D Laharie, P Bossuyt, Y Bouhnik, A Buisson, ... Clinical Gastroenterology and Hepatology 18 (3), 637-646. e11, 2020 | 79 | 2020 |
| How, when, and for whom should we perform therapeutic drug monitoring? S Vermeire, E Dreesen, K Papamichael, MC Dubinsky Clinical Gastroenterology and Hepatology 18 (6), 1291-1299, 2020 | 78 | 2020 |
| Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases E Dreesen, P Bossuyt, D Mulleman, A Gils, D Pascual-Salcedo Clinical pharmacology: advances and applications, 101-111, 2017 | 74 | 2017 |
| A genetic variation in the neonatal Fc-receptor affects anti-TNF drug concentrations in inflammatory bowel disease T Billiet, E Dreesen, I Cleynen, WJ Wollants, M Ferrante, G Van Assche, ... Official journal of the American College of Gastroenterology| ACG 111 (10 …, 2016 | 62 | 2016 |
| Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease K van Hoeve, E Dreesen, I Hoffman, G Van Assche, M Ferrante, A Gils, ... Journal of Crohn's and Colitis 12 (11), 1316-1325, 2018 | 60 | 2018 |
| Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples A Gils, T Van Stappen, E Dreesen, R Storme, S Vermeire, PJ Declerck Inflammatory bowel diseases 22 (4), 969-975, 2016 | 53 | 2016 |
| Anti‐infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response E Dreesen, T Van Stappen, V Ballet, M Peeters, G Compernolle, S Tops, ... Alimentary pharmacology & therapeutics 47 (3), 346-355, 2018 | 47 | 2018 |
| Peak concentrations of ustekinumab after intravenous induction therapy identify patients with Crohn’s disease likely to achieve endoscopic and biochemical remission J Hanžel, J Zdovc, T Kurent, N Sever, K Javornik, K Tuta, M Koželj, ... Clinical Gastroenterology and Hepatology 19 (1), 111-118. e10, 2021 | 40 | 2021 |
| Subcutaneous absorption contributes to observed interindividual variability in adalimumab serum concentrations in Crohn’s disease: a prospective multicentre study N Vande Casteele, F Baert, S Bian, E Dreesen, G Compernolle, ... Journal of Crohn's and Colitis 13 (10), 1248-1256, 2019 | 38 | 2019 |
| Adequate infliximab exposure during induction predicts remission in paediatric patients with inflammatory bowel disease K van Hoeve, E Dreesen, I Hoffman, G Van Assche, M Ferrante, A Gils, ... Journal of pediatric gastroenterology and nutrition 68 (6), 847-853, 2019 | 38 | 2019 |
| Antibodies toward vedolizumab appear from the first infusion onward and disappear over time S Bian, E Dreesen, HT Tang, G Compernolle, M Peeters, G Van Assche, ... Inflammatory bowel diseases 23 (12), 2202-2208, 2017 | 35 | 2017 |
| Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders ES Ward, D Gelinas, E Dreesen, J Van Santbergen, JT Andersen, ... Frontiers in immunology 13, 892534, 2022 | 34 | 2022 |
| Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-tumour necrosis factor [TNF] naïve and anti-TNF exposed IBD patients B Verstockt, E Mertens, E Dreesen, A Outtier, M Noman, S Tops, ... Journal of Crohn's and Colitis 14 (3), 332-341, 2020 | 34 | 2020 |
| Optimising infliximab induction dosing for patients with ulcerative colitis E Dreesen, R Faelens, G Van Assche, M Ferrante, S Vermeire, A Gils, ... British Journal of Clinical Pharmacology 85 (4), 782-795, 2019 | 30 | 2019 |
| Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial L Liesenborghs, I Spriet, D Jochmans, A Belmans, I Gyselinck, ... EBioMedicine 66, 2021 | 26 | 2021 |
Konstantinos PapamichailBeth Israel Deaconess Medical CenterVerified email at bidmc.harvard.edu
